Earnings · China A-shares
Staidson (Beijing) Biopharmaceuticals Co. Ltd. Class A (300204) earnings
Staidson (Beijing) Biopharmaceuticals Co. Ltd. Class A published its Q3 report on 2026-10-29: net profit -70.97% year on year, -58.26% excluding one-off items. Wave Radar's earnings-quality score is 59 of 100 (Questionable). The stock moved -1.41% in the 3 trading days after the report.
- Report
- Q3 report
- Published
- 2026-10-29
- Period end
- 2026-09-30
- Net profit YoY
- -70.97%
- Excl. one-offs YoY
- -58.26%
- Result
- Bad / loss
- Quality score
- 59
- Quality
- Questionable
Stock move after the report
Trading days from the first tradeable session; dividend-adjusted. "vs index" is the excess return over CSI 300 for A-shares.
| After | Return | vs index |
|---|---|---|
| 1 day | -1.47% | — |
| 3 days | -1.41% | — |
| 7 days | +3.42% | — |
| 14 days | -6.24% | — |
Report history
Over the last 8 reports, net profit grew year on year in 3 of them. The stock rose in the 3 trading days after 4 of 7 reports (average -0.83%).
| Report | Published | Net profit | Profit YoY | Excl. one-offs YoY | Revenue YoY | EPS | ROE | 3 days after | 30 days after | 30d vs index |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026 Q3 report | 2026-10-30 | -¥52.47M | -70.97% | -58.26% | -18.47% | -0.11 | -4.88% | -1.41% | — | — |
| 2026 interim report | 2026-08-25 | -¥36.77M | -49.25% | -36.58% | -26.03% | -0.08 | -4.52% | +4.19% | -5.67% | +0.36% |
| 2026 Q1 report | 2026-04-28 | -¥8.43M | -261.10% | — | -25.81% | -0.02 | -1.03% | +0.44% | -25.92% | -25.30% |
| 2025 annual report | 2026-04-28 | -¥77.76M | +46.31% | +46.74% | -32.20% | -0.16 | -8.89% | +0.44% | -25.92% | -25.30% |
| 2025 Q3 report | 2025-10-29 | -¥30.69M | -227.71% | — | -30.82% | -0.06 | -3.41% | +13.18% | -16.61% | -13.14% |
| 2025 interim report | 2025-08-26 | -¥24.64M | -619.70% | — | -31.14% | -0.05 | -2.70% | -14.79% | -47.16% | -48.84% |
| 2025 Q1 report | 2025-04-25 | -¥2.34M | +38.05% | +23.93% | -33.45% | 0.00 | -0.26% | -9.05% | +161.81% | +158.56% |
| 2024 annual report | 2025-03-25 | -¥144.84M | +63.69% | +62.19% | -10.81% | -0.30 | -15.04% | +1.65% | +51.65% | +55.26% |
The last 8 reports. Net profit is attributable to shareholders and year-to-date (a Q3 report covers the first nine months). Moves count trading days from the first tradeable session after publication; "30d vs index" is the excess return over CSI 300.
How to read this
Results are grouped by reported profit growth (great, good, neutral, bad or a loss). For China A-shares the quality score starts at 100 and loses points for gaps a reader can check: operating cash falling short of profit, receivables or inventory outrunning revenue, profit that rests on one-off items or subsidies, heavy goodwill and a qualified audit opinion.
Figures are generated automatically from Wave Radar's published market data and refresh after each market close.